Author Julia DeVillers was daignosed with anal cancer and as it progresses, she was told she had 48 hours to live. Her ...

FDA-approved as the first and only approved first line treatment for advanced squamous cell carcinoma of the anal canal.

Cases of anal cancer have been rising significantly across the world, with doctors being able to identify who is at the most ...

With two concurrent FDA approvals, Incyte’s PD-1 inhibitor Zynyz has redeemed itself in anal cancer four years after an ...

White women over 65 experienced the most significant increase, with rates climbing 4.3% annually to reach 11.4 cases per ...

PD-1 antibody was approved as first-line treatment for locally recurrent or metastatic squamous cell anal carcinoma.

A kinder treatment for anal cancer involving a lower dose and shorter course of radiotherapy is more effective than ...

The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported ...

These findings highlight specific patient groups who may benefit from targeted screening for anal HPV and anal cancer,” said lead study author Dr. Ashley Robinson.

The latecomer PD-1 inhibitor – already approved for Merkel cell carcinoma – has become the first cancer immunotherapy for ...

Patients and clinicians have welcomed the results of the ACT4 PLATO trial, which was the first clinical trial in the world to ...

Anal cancer rates are increasing most rapidly among white and Hispanic women over 65, a group not traditionally seen as ...